Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
This is a single center collection of discarded biological samples and electronic medical
 review (EMR) data on patients who are hospitalized with clostridium difficile infections and
 treated with Fidaxomicin
This single site study will be a clinical research data base of patients hospitalized and
 diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to
 allow us to collect discard biological samples for testing and analysis in the investigators
 lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is
 performed as to measure the amount of medication in the BAL. We will also complete a medical
 record review will also occur.
Inclusion Criteria:

 1. ≥18 years of age

 2. Currently an inpatient at UPMC Presbyterian

 3. Diagnosed with an CDI

 4. Being treated with Fidaxomicin

 Exclusion Criteria:

 not meeting entry criteria